Manon Mulders

Manon Mulders

Auto-generated profile, based on publicly available information

Manon Mulders

Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CMCrescenzo Massaro
Crescenzo Massaro
HSHilal N. Sensoy
Hilal N. Sensoy
MMManon Mulders
Manon Mulders
CSCeline De Schrijver
Celine De Schrijver
CGCristina Gómez-Martín
Cristina Gómez-Martín
SBSerena Rubina Baglio
Serena Rubina Baglio
Purpose: Therapy resistance is a major clinical hurdle in bone cancer treatment and seems to be largely driven by poorly understood microenvironmental factors. Recent evidence suggests a critical role for a unique subpopulation of mesenchymal stem cells with inflammatory features (iMSC), though their origin and function remained unexplored. We demonstrate that cancer-secreted extracellular vesicles (EV) trigger the development of iMSCs, which hinder therapy response in vivo, and set out to identify strategies to counteract their function. Experimental Design: The role of iMSCs in therapy resistance was evaluated in an orthotopic xenograft mouse model of osteosarcoma. EV-induced alterations of the MSC transcriptome were analyzed and compared with single-cell RNA sequencing data of biopsies from patients with osteosarcoma and multiple myeloma. Functional assays identified EV components driving iMSC development. We assessed the efficacy of clinical drugs in blocking iMSC-induced resistance in vivo. Results: We found that iMSCs are induced by interaction with cancer EVs and completely abrogate the antimetastatic effect of TGFβ signaling inhibition. Importantly, EV-induced iMSCs faithfully recapitulate the inflammatory single-cell RNA signature of stromal cells enriched in biopsies from patients with multiple myeloma and osteosarcoma. Mechanistically, cancer EVs act through two distinct mechanisms. EV-associated TGFβ induces IL6 production, whereas the EV-RNA cargo enhances TLR3-mediated chemokine production. We reveal that simultaneous blockade of downstream EV-activated pathways with ladarixin and tocilizumab disrupts metastasis formation and overcomes iMSC-induced resistance. Conclusions: Our observations establish iMSCs as major contributors to drug resistance, reveal EVs as triggers of iMSC development, and highlight a promising combination strategy to improve therapy response in patients with bone cancer.

15 October 2024
Verified
Other
Open access
PDF file
CMCrescenzo Massaro
Crescenzo Massaro
HSHilal N. Sensoy
Hilal N. Sensoy
MMManon Mulders
Manon Mulders
CSCeline De Schrijver
Celine De Schrijver
CGCristina Gómez-Martín
Cristina Gómez-Martín
SBSerena Rubina Baglio
Serena Rubina Baglio
Suppl. Figure 7. a) Dynasore-mediated inhibition of PKH67-labeled EV uptake by MSCs as assessed by FACS. b-e) Relative expression levels of CXCL2, CXCL5, CXCL3, CXCL6 in MSCs treated with 143B EVs in the presence or absence of dynasore. Transcript levels are normalized to GAPDH and expressed as fold increase relative to the experimental controls (untreated or dynasore-treated MSCs). Graphs show the average of 3 (CXCL2 and CXCL6) or 2 (CXCL3 and CXCL5) experiments. Statistics was calculated on normalized expression data, *p < 0.05, two-tailed t test. f) Volcano plots depicting differentially expressed interferon stimulated genes (ISGs) in MSCs exposed to 143B EVs, and relative log2FC and FDR values. Human fibroblast (hF) EVs were used as control vesicles. g-j) Expression of the ISGs IFIT1, IFITM1, MX1 and OAS2 in BM-MSCs upon transfection with (143B) EV RNA pre-treated or not with RNase III or RNase A. k-n) Syntenin, IL8, CXCL2 and CXCL3 mRNA expression levels in 143B stably transduced with dox-inducible shRNAs against syntenin or GFP as non-targeting control, in the presence or absence of doxycycline. o-r) RAB35, IL8, CXCL2 and CXCL3 mRNA expression levels in 143B stably transduced with dox-inducible shRab35 or shGFP in the presence or absence of doxycycline.

15 October 2024
Verified
Other
Open access
PDF file
CMCrescenzo Massaro
Crescenzo Massaro
HSHilal N. Sensoy
Hilal N. Sensoy
MMManon Mulders
Manon Mulders
CSCeline De Schrijver
Celine De Schrijver
CGCristina Gómez-Martín
Cristina Gómez-Martín
SBSerena Rubina Baglio
Serena Rubina Baglio
Suppl. Figure 5. a-b) CD63 (a) and CD81 (b) protein quantification (western blot pixel density) in EVs released by engineered (shGFP, shSyntenin, shRab11b, shRab35) 143B cells. c) Growth curve of wt and engineered (shGFP, shRab11b, shRab35, shSyntenin) 143B showing no differences in cell growth over 72 hours). d-e) Relative mRNA expression levels of IL6 (d) and IL8 (e) in MSCs exposed to indicated volumes of wild type 143B EVs.

15 October 2024
Verified
Other
Open access
PDF file
CMCrescenzo Massaro
Crescenzo Massaro
HSHilal N. Sensoy
Hilal N. Sensoy
MMManon Mulders
Manon Mulders
CSCeline De Schrijver
Celine De Schrijver
CGCristina Gómez-Martín
Cristina Gómez-Martín
SBSerena Rubina Baglio
Serena Rubina Baglio
Suppl. Figure 3. a-e) Relative expression levels of IL6, IL8, CXCL2, CXCL3 and CXCL6 in MSCs from an independent donor (MSC#2) exposed to plasma-derived EVs from healthy donor #1 (H#1) and MM patient #1 (MM#1).

15 October 2024
Verified
Other
Open access
PDF file
CMCrescenzo Massaro
Crescenzo Massaro
HSHilal N. Sensoy
Hilal N. Sensoy
MMManon Mulders
Manon Mulders
CSCeline De Schrijver
Celine De Schrijver
CGCristina Gómez-Martín
Cristina Gómez-Martín
SBSerena Rubina Baglio
Serena Rubina Baglio
Suppl. Figure 6. a-b) Expression of the most upregulated TGFβ-dependent (a) and independent/partially dependent (b) genes in bone marrow MSCs based on RNA-seq normalized counts. c-f) Relative expression levels of CXCL1, CXCL2, CXCL5, CXCL6 mRNAs in bone marrow MSCs (donor #1) exposed to 143B EVs in the presence or absence of the TGFBR1 inhibitor SB-431542 as assessed by RT-qPCR. g-m) Relative expression levels of IL6, IL8, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 mRNAs in bone marrow MSCs (donor #2) exposed to 143B EVs in the presence or absence of the TGFBR1 inhibitor EW-7197. n-o) Relative expression of IL6 and IL8 mRNAs in adipose-derived MSCs (donor #3) exposed to 143B EVs in the presence or absence of EW-7197.